Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia, Normal Cytogenetics, and the FLT3-ITD Mutation

Overview

Journal Leuk Res

Date 2015 Dec 23

PMID 26692109

Citations 3

Authors

Ellin Berman

Molly Maloy

Sean Devlin

Suresh Jhanwar

Esperanza Papadopoulos

Ann Jakubowski

Affiliations

Soon will be listed here.

Abstract

Following chemotherapy, patients with acute myelogenous leukemia (AML), normal cytogenetics, and the FLT3-ITD mutation have shorter survival compared to wild type (WT) patients. To determine the role of stem cell transplantation (SCT), we performed a retrospective review of adult patients with AML who underwent SCT at our center between January 1, 2007 and December 31, 2011. Of the 200 patients transplanted, 79 patients (40%) had normal cytogenetics; of these, 17 (22%) had the FLT3-ITD mutation, 35 were WT (44%), and 27 (34%) did not have FLT3 testing performed. Clinical characteristics were similar in each group. At four years, overall survival (OS) between FLT3 positive and WT groups was similar: 0.54 (95% CI 0.29-0.75) versus 0.73 (95% CI 0.53-0.99), p=0.18. Relapse rates were also similar, 0.09 (95% CI 0.02-0.21) versus 0.12 (95% CI: 0.02-0.32); p=0.67. We conclude that SCT can abrogate the poor prognosis in FLT3-ITD positive patients.

Citing Articles

The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant.

Li G, Wang L, Yaghmour B, Ramsingh G, Yaghmour G Leuk Res Rep. 2018; 10:26-36.

PMID: 30112274 PMC: 6092446. DOI: 10.1016/j.lrr.2018.06.003.

Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Poire X, Labopin M, Polge E, Passweg J, Craddock C, Blaise D Haematologica. 2017; 103(2):256-265.

PMID: 29242299 PMC: 5792270. DOI: 10.3324/haematol.2017.178251.

FLT3-ITD and its current role in acute myeloid leukaemia.

Lagunas-Rangel F, Chavez-Valencia V Med Oncol. 2017; 34(6):114.

PMID: 28470536 DOI: 10.1007/s12032-017-0970-x.

References

Fritsch G, Scharner D, Froschl G, Buchinger P, Peters C, Matthes S . Selection of CD34-Positive Blood Cells for Allogeneic Transplantation: Approaches to Optimize D34-Cell Recovery, Purity, Viability, and T-cell Depletion. Onkologie. 2001; 23(5):449-456. DOI: 10.1159/000027219. View

Lowenberg B, Downing J, Burnett A . Acute myeloid leukemia. N Engl J Med. 1999; 341(14):1051-62. DOI: 10.1056/NEJM199909303411407. View

Kekre N, Antin J . Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014; 124(3):334-43. DOI: 10.1182/blood-2014-02-514760. View

Devine S, Carter S, Soiffer R, Pasquini M, Hari P, Stein A . Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials.... Biol Blood Marrow Transplant. 2011; 17(9):1343-51. PMC: 3150599. DOI: 10.1016/j.bbmt.2011.02.002. View

Schlenk R, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M . Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014; 124(23):3441-9. DOI: 10.1182/blood-2014-05-578070. View

Buchner T, Schlenk R, Schaich M, Dohner K, Krahl R, Krauter J . Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol. 2012; 30(29):3604-10. DOI: 10.1200/JCO.2012.42.2907. View

Jakubowski A, Small T, Young J, Kernan N, Castro-Malaspina H, Hsu K . T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007; 110(13):4552-9. PMC: 2234775. DOI: 10.1182/blood-2007-06-093880. View

Byrd J, Mrozek K, Dodge R, Carroll A, Edwards C, Arthur D . Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100(13):4325-36. DOI: 10.1182/blood-2002-03-0772. View

Frohling S, Schlenk R, Breitruck J, Benner A, Kreitmeier S, Tobis K . Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002; 100(13):4372-80. DOI: 10.1182/blood-2002-05-1440. View

10.

Schlenk R, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L . Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358(18):1909-18. DOI: 10.1056/NEJMoa074306. View

11.

Ponce D, Sauter C, Devlin S, Lubin M, Gonzales A, Kernan N . A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. Biol Blood Marrow Transplant. 2013; 19(5):799-803. PMC: 3673764. DOI: 10.1016/j.bbmt.2013.02.007. View

12.

Kayser S, Schlenk R, Correa Londono M, Breitenbuecher F, Wittke K, Du J . Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009; 114(12):2386-92. DOI: 10.1182/blood-2009-03-209999. View

13.

Meshinchi S, Stirewalt D, Alonzo T, Boggon T, Gerbing R, Rocnik J . Structural and numerical variation of FLT3/ITD in pediatric AML. Blood. 2008; 111(10):4930-3. PMC: 2384125. DOI: 10.1182/blood-2008-01-117770. View

14.

Gale R, Hills R, Kottaridis P, Srirangan S, Wheatley K, Burnett A . No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005; 106(10):3658-65. DOI: 10.1182/blood-2005-03-1323. View

15.

DeZern A, Sung A, Kim S, Smith B, Karp J, Gore S . Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant. 2011; 17(9):1404-9. PMC: 3110512. DOI: 10.1016/j.bbmt.2011.02.003. View

16.

Michallet M, Sobh M, Serrier C, Morisset S, Labussiere H, Ducastelle S . Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings. Leuk Lymphoma. 2014; 56(4):999-1003. DOI: 10.3109/10428194.2014.944518. View

17.

Small T, Young J, Castro-Malaspina H, Prockop S, Wilton A, Heller G . Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant. 2007; 13(2):235-44. DOI: 10.1016/j.bbmt.2006.10.005. View

18.

Tefferi A, Letendre L . Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia. J Clin Oncol. 2012; 30(20):2425-8. DOI: 10.1200/JCO.2011.38.9601. View

19.

Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T . The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. Blood. 2012; 119(19):4383-6. DOI: 10.1182/blood-2010-12-327072. View

20.

Keating M, Smith T, Kantarjian H, Cork A, Walters R, Trujillo J . Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia. 1988; 2(7):403-12. View